↓ Skip to main content

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

Overview of attention for article published in Investigational New Drugs, January 2008
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
47 Dimensions

Readers on

mendeley
31 Mendeley
Title
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
Published in
Investigational New Drugs, January 2008
DOI 10.1007/s10637-008-9112-9
Pubmed ID
Authors

Patricia M. LoRusso, Shirish M. Gadgeel, Antoinette Wozniak, Alan J. Barge, Helen K. Jones, Zachary S. DelProposto, Pamela A. DeLuca, Jeffrey L. Evelhoch, Scott A. Boerner, Catherine Wheeler

Abstract

ZD6126 is a novel vascular-targeting agent that disrupts the endothelial tubulin cytoskeleton causing selective occlusion of tumor vasculature and extensive tumor necrosis. This Phase I clinical study was conducted to evaluate the dose and administration schedule of ZD6126.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 6%
Unknown 29 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 23%
Unspecified 6 19%
Student > Master 5 16%
Researcher 4 13%
Other 2 6%
Other 7 23%
Readers by discipline Count As %
Chemistry 9 29%
Medicine and Dentistry 8 26%
Agricultural and Biological Sciences 6 19%
Unspecified 5 16%
Neuroscience 1 3%
Other 2 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2009.
All research outputs
#3,544,457
of 12,335,419 outputs
Outputs from Investigational New Drugs
#130
of 643 outputs
Outputs of similar age
#80,549
of 270,847 outputs
Outputs of similar age from Investigational New Drugs
#1
of 8 outputs
Altmetric has tracked 12,335,419 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 643 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,847 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them